FDA Hits Snooze Button on Neurocrine's Sleep Drug
Further clouding the future of insomnia drug Indiplon, Neurocrine Biosciences Inc. said on Tuesday that the FDA has asked it to reanalyze safety and efficacy data because of issues raised in...To view the full article, register now.
Already a subscriber? Click here to view full article